- Novo Holdings backs European fund; Alnylam sends second obesity drug into clinicPlus news about IMU Biosciences, Autobahn and Jade Biosciences. 💸 Novo Holdings invests in Europe-focused fund: The investment manager of the Novo Nordisk Foundation's fortunes is backing the Sc…Endpoints · 1mo ago↗ source
- Parabilis Medicines charts $413M IPO to back peptide pipelineParabilis Medicines, the peptide biotech led by former Johnson & Johnson R&D head Mathai Mammen, is seeking more than $400 million in its Nasdaq debut. If the drug developer follows throu…Endpoints · 1mo ago↗ source
- ADC Therapeutics' confirmatory data for Zynlonta muddied by death ratesADC Therapeutics’ bid to secure full approval for Zynlonta in relapsed or refractory diffuse large B-cell lymphoma has been complicated by death rates in its confirmatory trial. The company said ...